Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis

The amount of pevonedistat to be administered will be based on body surface area (BSA). BSA will be calculated using a standard formula on Cycle 1 Day 1, and on Day 1 of subsequent cycles if the patient experiences a \> 5% change in body weight from the weight used for the most recent BSA calculation.

-Standard of care outside of protocol

"* Baseline or Cycle 1 Day 1 (prior to study treatment administration)~* Cycle 2 Day 1 (prior to study treatment administration)~* Cycle 4 Day 1 (prior to study treatment administration)~* End of treatment"

A skin punch biopsy specimen will be collected at the baseline visit. One 6 mm punch biopsy of normal skin will be performed using standard techniques and local anesthesia.